Sort
15,842 grants matching “pancreatic cancer”
Human-Enzyme Mediated, Systemic Depletion of Cystine for Cancer Treatment.
$580,448George Georgiou Georgiou · University Of Texas At Austin · R01 · FY2014 · CA
Human-Enzyme Mediated, Systemic Depletion of Cystine for Cancer Treatment.
$580,448George Georgiou Georgiou · University Of Texas At Austin · R01 · FY2017 · CA
Human-Enzyme Mediated, Systemic Depletion of Cystine for Cancer Treatment.
$580,448George Georgiou Georgiou · University Of Texas At Austin · R01 · FY2015 · CA
Human-Enzyme Mediated, Systemic Depletion of Cystine for Cancer Treatment.
$580,448George Georgiou Georgiou · University Of Texas At Austin · R01 · FY2016 · CA
Serum Proteomic Biomarkers for Colon &Pancreatic Cancer
$580,277University Of Pittsburgh At Pittsburgh · U01 · FY2005 · CA
Comparative analysis between patient-derived models of pancreatic ductal adenocarcinomas and matched tumor specimens
$580,069Rosalie C Sears · Oregon Health & Science University · U01 · FY2019 · CA
TBEL Project 3
$580,040Laura Delong Wood · University Of Tx Md Anderson Can Ctr · U54 · FY2023 · CA
Mouse Models of Gastrointestinal Cancer
$579,936Ohio State University · U01 · FY2005 · CA
The non-catalytic function of PARP2 in DNA repair and cancer therapy
$579,845Shan Zha · Columbia University Health Sciences · R01 · FY2023 · CA
Targeting Stromal Influences on BCKA Addiction in PDAC Tumors
$579,715Deepak Nagrath · University Of Michigan At Ann Arbor · R01 · FY2023 · CA
Translational Applications in an Animal Model of Pancreatic Cystic Neoplasm and Cancer
$579,669Anirban Maitra · University Of Tx Md Anderson Can Ctr · R01 · FY2019 · CA
Exposure and biological response biomarkers of cigarette smoke
$579,444Ian Alexander Blair · University Of Pennsylvania · U01 · FY2010 · ES
Homologous recombination deficiency and beyond in pancreatic cancer: evaluating the regulators of response to pembrolizumab and olaparib (POLAR) from the immune and genomic perspectives
$579,257Eileen Mary O'Reilly · Sloan-Kettering Inst Can Research · P50 · FY2024 · CA
HIFU-immunotherapy in pancreatic cancer
$579,183Katherine W Ferrara · Stanford University · R01 · FY2024 · CA
High-Performance High-Field Parallel MRI.
$578,715Daniel K Sodickson · New York University School Of Medicine · R01 · FY2013 · EB
Determinants of pancreatic cancer and malignant melanoma phenotypes in CDKN2A hereditary kindreds
$578,620Gloria M. Petersen · Mayo Clinic Rochester · R01 · FY2016 · CA
Enhancing Chemoradiation Efficacy through Unbiased Drug Discovery Approaches
$578,444Steven Hsesheng Lin · University Of Tx Md Anderson Can Ctr · U01 · FY2019 · CA
Sensitization to Chemoradiation by Therapeutic Targeting of the DNA Damage Response
$578,379Theodore S Lawrence · University Of Michigan At Ann Arbor · U01 · FY2017 · CA
Elucidating the Immune Suppressive Mechanism of SIGLEC-15 in the Tumor Microenvironment
$578,201Jun Wang · New York University School Of Medicine · R01 · FY2025 · CA
Targeting Pancreatic Cancer Using Peptide Chemistry: From Bench to Bedside
$577,974Debabrata Mukhopadhyay · Mayo Clinic Rochester · R01 · FY2011 · CA
Development of irreversible electroporation-based rational combinations to potentiate the activity of cancer immunotherapy against pancreatic ductal adenocarcinoma
$577,925Chun Li · University Of Tx Md Anderson Can Ctr · R01 · FY2025 · CA
ProAgio in Pancreatic Cancer
$577,819Bassel El-Rayes · University Of Alabama At Birmingham · R01 · FY2025 · CA
Project 2: Identifying Metabolic vulnerabilities and targets in cancers with mutations in hamartoma genes
$577,690David J. Kwiatkowski · Brigham And Women'S Hospital · P01 · FY2019 · CA
Biomolecular Recognition and Binding Mechanisms
$577,321Ruth Nussinov · Division Of Basic Sciences - Nci · ZIA · FY2016 · CA
Discovery of Glutaryl-CoA Dehydrogenase inhibitors for melanoma and pancreatic cancer
$577,198Eduard A. Sergienko · Sanford Burnham Prebys Medical Discovery Institute · R01 · FY2024 · CA